ERBB2 and neoplasm: Similarly, use of EGFR TKIs in lung cancer show improved response rates (50–80%), but the emergence of intrinsic or acquired resistance, for example, the emergence of EGFR-T790M mutations or the activation of other signaling pathways including MET, AXL, IGF1R, IL-6R, HER2, and HER352, often results in tumor relapse and progressive disease.